Recent Posts

• Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform May 8, 2023
• Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update March 30, 2023
• Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023